We're honored to have Dr. Michael Kauffman, M.D., Ph.D., the Chief Executive Officer of Nereid Therapeutics, joining us.Dr. Kauffman brings over 25 years of experience in the life sciences industry, with a distinguished track record in oncology drug development. Currently, he leads Nereid Therapeutics, a company at the forefront of pioneering therapies targeting biomolecular condensates—a novel approach to treating complex diseases. Under his leadership, Nereid is advancing multiple programs in oncology and neurodegeneration toward clinical application. PR NewswirePrior to his role at Nereid, Dr. Kauffman co-founded Karyopharm Therapeutics, where he served as CEO and guided the company from discovery to the global approval of XPOVIO® for multiple myeloma and non-Hodgkin’s lymphoma. His extensive experience also includes leadership positions at Onyx Pharmaceuticals, Millennium Pharmaceuticals, and Biogen. Dr. Kauffman earned his M.D. and Ph.D. from Johns Hopkins Medical School and completed his training in Internal Medicine at Beth Israel Deaconess Medical Center and in Rheumatology at Massachusetts General Hospital. He is board-certified in Internal Medicine and licensed in Massachusetts and Florida. In this episode, we'll delve into Dr. Kauffman's journey in the biotech industry, the innovative science behind Nereid's approach, and the future of targeted therapies in treating complex diseases.